How does a protein with dual mitotic spindle and extracellular matrix receptor functions affect tumor susceptibility and progression?

Communicative and Integrative Biology

Volumn 4, Issue 2, 2011, Pages 182-185

  Telmer, Patrick G ^a   Tolg, Cornelia ^a   McCarthy, James B ^b   Turley, Eva A ^a  

^a WESTERN UNIVERSITY   (Canada)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Cancer biology; CD168; Cell cycle; Cell migration; Hmmr; MAPK; Mitosis; Rhamm

Indexed keywords

EID: 80155136185     PISSN: None     EISSN: 19420889     Source Type: Journal    
DOI: 10.4161/cib.4.2.14270     Document Type: Article

References (22)

1. Crainie M, Belch AR, Mant MJ, Pilarski LM. Overexpression of the receptor for hyaluronan-mediated motility (RHAMM) characterizes the malignant clone in multiple myeloma: Identification of three distinct RHAMM variants. Blood 1999; 93:1684-96.
2. + T-cell responses in patients with chronic lymphocytic leukemia. Leukemia 2006; 24:798-805.
3. Greiner J, Ringhoffer M, Taniguchi M, Schmitt A, Kirchner D, Krähn G, et al. Receptor for hyaluronan acid-mediated motility (RHAMM) is a new immunogenic leukemia-associated antigen in acute and chronic myeloid leukemia. Exp Hematol 2002; 30:1029-35.
4. Greiner J, Schmitt A, Giannopoulos K, Rojewski MT, Götz M, Funk I, et al. High dose RHAMM-R3 peptide vaccination for patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and multiple myeloma (MM). Haematologica 2010; 95:1191-7.
5. Gust KM, Hofer MD, Perner SR, Kim R, Chinnaiyan AM, Varambally S, et al. RHAMM (CD168) is overexpressed at the protein level and may constitute an immunogenic antigen in advanced prostate cancer disease. Neoplasia 2009; 11:956-63.
6. Kalmyrzaev B, Pharoah PD, Easton DF, Ponder BA, Dunning AM. Hyaluronan-mediated motility receptor gene single nucleotide polymorphisms and risk of breast cancer. Cancer Epidemiol Biomarkers Prev 2008; 17:3618-20.
7. Maxwell CA, Keats JJ, Belch AR, Pilarski LM, Reiman T. Receptor for hyaluronan-mediated motility correlates with centrosome abnormalities in multiple myeloma and maintains mitotic integrity. Cancer Res 2005; 65:850-60.
8. Maxwell CA, McCarthy J, Turley E. Cell-surface and mitotic-spindle RHAMM: Moonlighting or dual oncogenic functions? J Cell Sci 2008; 121:925-32.
9. Nagel S, Hirschmann P, Dirnhofer S, Gunthert U, Tzankov A. Coexpression of CD44 variant isoforms and receptor for hyaluronic acid-mediated motility (RHAMM, CD168) is an international prognostic index and C-MYC gene status-independent predictor of poor outcome in diffuse large B-cell lymphomas. Exp Hematol 2010; 38:38-45.
10. Schmitt M, Schmitt A, Rojewski MT, Chen J, Giannopoulos K, Fei F, et al. RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma elicits immunologic and clinical responses. Blood 2008; 111:1357-65.
11. Tabarkiewicz J, Giannopoulos K. Definition of a target for immunotherapy and results of the first peptide vaccination study in chronic lymphocytic leukemia. Transplant Proc 2010; 42:3293-6.
12. Hamilton SR, Fard SF, Paiwand FF, Tolg C, Veiseh M, Wang C, et al. The hyaluronan receptors CD44 and rhamm (CD168) form complexes with ERK1,2 that sustain high basal motility in breast cancer cells. J Biol Chem 2007; 282:16667-80.
13. Turley EA, Noble PW, Bourguignon LY. Signaling properties of hyaluronan receptors. J Biol Chem 2002; 277:4589-92.
14. -/- fibroblasts are defective in CD44-mediated ERK1,2 motogenic signaling, leading to defective skin wound repair. J Cell Biol 2006; 175:1017-28.
15. Joukov V, Groen AC, Prokhorova T, Gerson R, White E, Rodriguez A, et al. The BRCA1/BARD1 heterodimer modulates ran-dependent mitotic spindle assembly. Cell 2006; 127:539-52.
16. Groen AC, Cameron LA, Coughlin M, Miyamoto DT, Mitchison TJ, Ohi R. XRHAMM functions in ran-dependent microtubule nucleation and pole formation during anastral spindle assembly. Curr Biol 2004; 14:1801-11.
17. Tolg C, Hamilton SR, Morningstar L, Zhang J, Zhang S, Esguerra KV, et al. RHAMM promotes interphase microtubule instability and mitotic spindle integrity through MEK1/ERK1/2 activity. J Biol Chem 2010; 285:26461-74.
18. Song L, Rape M. Regulated degradation of spindle assembly factors by the anaphase-promoting complex. Mol Cell 2010; 38:369-82.
19. Maxwell CA, Keats JJ, Crainie M, Sun X, Yen T, Shibuya E, et al. RHAMM is a centrosomal protein that interacts with dynein and maintains spindle pole stability. Mol Biol Cell 2003; 14:2262-76.
20. Vaidyanathan H, Opoku-Ansah J, Pastorino S, Renganathan H, Matter ML, Ramos JW. ERK MAP kinase is targeted to RSK2 by the phosphoprotein PEA-15. Proc Natl Acad Sci USA 2007; 104:19837-42.
21. Appel S, Allen PG, Vetterkind S, Jin JP, Morgan KG. h3/Acidic calponin: An actin-binding protein that controls extracellular signal-regulated kinase1/2 activity in nonmuscle cells. Mol Biol Cell 2010; 21:1409-22.
22. Levchenko A, Bruck J, Sternberg PW. Scaffold proteins may biphasically affect the levels of mitogenactivated protein kinase signaling and reduce its threshold properties. Proc Natl Acad Sci USA 2000; 97:5818-23.